CSPI and CFA letter to Congress re: CBD
Congress urged to entrust FDA with authority to determine product safety
CSPI and the Consumer Federation of America write to urge the Congress not to act on its own initiative to open a pathway to legalize cannabidiol (CBD) in dietary supplements or food products. Congress is not the right evaluator of the safety of products, and it should ensure that this critical job remains in the hands of the Food and Drug Administration (FDA). The FDA currently lacks adequate legal authority to assure consumer safety and the consistency or quality of products containing CBD that may be sold as dietary supplements or in food.
Congress should provide more authority for FDA to ensure the safety of supplements containing CBD, and in general. FDA should be asked to end or prevent the practice of secret GRAS determinations for CBD in food or supplements and clarify that self-determined GRAS is not an appropriate compliance pathway for such products, CSPI and CFA argue.